Black Diamond TherapeuticsBDTX
Recorded

Black Diamond Therapeutics Study update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration35 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and thank you for standing by. Welcome to the silevertinib Program Update webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's webcast is being recorded. I would like to hand the presentation over to your first speaker today, Mark Velleca, CEO of Black Diamond Therapeutics.

Mark VellecaCEO

Mark, please go ahead. Thank you, operator, and thank you all for joining today's webcast.

Mark VellecaCEO

We are excited to provide an update on silevertinib, which we believe is a best-in-class EGFR TKI for patients with non-small cell lung cancer and glioblastoma. After my introductory remarks, Sergey Yurasov, Chief Medical Officer, will present updated phase II results in frontline patients with non-small cell lung cancer, key takeaways from our end-of-phase II meeting with the FDA, and our pivotal development plans. He will also provide a brief update on our GBM program. I will make some closing comments, and then our Chief Scientific Officer, Liz Buck, will join us for Q&A. Before I go further, I would like to remind you that during today's webcast, we will be making forward-looking statements, and actual results could differ materially. Please refer to the disclaimer on this slide and the risk factors in our recent SEC filings.

Mark VellecaCEO

Our webcast will focus on a key determinant of progression in patients with EGFR mutant non-small cell lung cancer, brain metastases. We know that approximately 40% of patients with non-classical mutations, or NCMs, present with brain metastases at diagnosis, and approximately 80% of patients with NCMs will eventually progress in the brain. Because of this fact, overall response rate is often not a strong predictor of progression-free survival. Simply put, if a therapy can delay progression in the brain, patients have an opportunity to live longer. Based on our recent end-of-phase II meeting with the FDA, it is clear that they recognize the importance of controlling brain metastases to deliver meaningful survival benefit to patients. Today, we are excited to share with you new analyses of our phase II data in patients with and without brain metastases.

Mark VellecaCEO

As you will hear from Sergey, these data are highly compelling and demonstrate progression-free survival that is twice that of available TKIs. These data drove a highly productive and collaborative meeting with the agency last month regarding our phase III plans. We came away with a clear definition of our patient population, patients with all non-classical mutations, and a primary endpoint of CNS overall response rate for potential accelerated approval. Both of these outcomes make silevertinib's path to potential approval differentiated from any other TKI in development. Finally, the FDA acknowledged our justification for our pivotal dose of 150 milligrams. We have been enrolling patients at that dose for the past three months, and we will submit data from that cohort to the FDA prior to our planned phase III trial, which we expect to initiate in the second quarter of 2027.

Mark VellecaCEO

Before I highlight the data from patients with and without brain metastases, the results from the overall ITT population of 43 patients has not changed since ASCO. Systemic ORR and median PFS remain at 60% and 15 months, respectively. The data from patients with and without brain metastases are unprecedented. In patients with untreated brain metastases, silevertinib generated an 86% CNS ORR, which compares to a 35%-36% CNS ORR seen with afatinib and osimertinib from published data. In patients with untreated brain metastases, silevertinib delivered 12.2 months of median progression-free survival, doubling the median progression-free survival of afatinib and osimertinib from published data. In patients without brain metastases, silevertinib delivered 23.5 months median PFS, compared with 9.8 months seen with osimertinib historically. At ASCO, we reported that none of these 24 patients had progressed in the brain.

Mark VellecaCEO

Now, we are thrilled to report that with a median follow-up time of nearly 16 months, that is still the case. Not a single patient has developed a brain metastasis. We're focusing on patients with non-classical EGFR mutations. They represent about a quarter of newly diagnosed cases of EGFR-mutated lung cancer, and you can see that in the pie chart on the left. There are over 50 mutations that make up the group of non-classical mutations, and silevertinib potently targets all of them. This is one of the big wins from our FDA meeting. They also agree with this definition of mutations for our patient population. We're not limited to PACC mutations, which make up only half of these non-classical mutations. Our patient population is this entire piece of the pie.

Mark VellecaCEO

The reason why the FDA acknowledges this full group for silevertinib is because we've already demonstrated confirmed radiographical responses in so many of these mutations. When you think about trial enrollment or even an eventual label, this is a major win because it's so easy to understand as a physician. A patient can come onto our trial if they have an oncogenic EGFR mutation other than a classical mutation or an exon 20 insertion. Of note, silevertinib is also very active against classical mutations, and in preclinical studies, is 10 times more potent on L858R as compared to osimertinib. We believe this, combined with silevertinib's robust CNS activity, affords multiple potential opportunities to develop silevertinib in other patient population and lines of therapy, especially in the adjuvant setting. With that, I'll turn it over to Sergey to discuss our recent data, FDA feedback, and phase III plan.

Sergey YurasovChief Medical Officer

Thank you, Mark. First, a quick reminder of the phase II study we'll be discussing today. We enrolled 43 patients in the frontline phase II cohort, all in the United States and Canada. This is critical because, as we all know, EGFR TKI studies conducted primarily in Asia can produce early data that do not always stand up in global trials. Our trial also enrolled a real-world patient population with over 33 unique non-classical mutations, unlike other trials which enrolled a much smaller number of mutations. The data we presented at ASCO this past May had 11 months of median follow-up, and now, with almost 16 months of median follow-up, we see that the systemic ORR and median PFS are mature and maintained. We're also seeing striking CNS activity and evidence that sotorasib is delaying progression in the brain in both patients with and without brain metastasis.

Sergey YurasovChief Medical Officer

Well, let's talk about this striking CNS activity now, because it is the key driver of the durable benefit we are seeing in patients both with or without baseline brain metastasis. These robust data drove our FDA conversation and laid the foundation for our unique phase III design. First, silevertinib has shown the strongest brain penetrance of any EGFR TKI out there right now. As seen in the panel on the left, silevertinib is the only EGFR TKI to demonstrate high levels of unbound drug directly measured in brain tumors from treated patients. As shown in the histograms, silevertinib achieves high concentrations in both non-contrast-enhancing and contrast-enhancing tumor regions, well above the threshold of 5x IC50. This means that silevertinib crosses an intact blood-brain barrier to deeply penetrate all areas of the tumor. Inability to cross the blood-brain barrier is a significant limitation of most other drugs.

Sergey YurasovChief Medical Officer

The next panel is our phase II results in frontline patients showing an 86% CNS ORR per RANO-BM criteria in patients with baseline brain metastasis who received no prior radiation treatment to the brain. That's a critical piece, because many other studies report CNS responses from patients who have been pre-treated with radiation. Furthermore, RANO-BM criteria are more stringent than RECIST. FDA only accepts CNS ORR per RANO-BM to evaluate CNS activity. The 86% CNS ORR for silevertinib is more than double the historical CNS ORR data for osimertinib and afatinib. Of course, it's not just the response rate that matter. Durability is also critical. Our median PFS is more than 12 months, while you can see benchmarks with osimertinib and afatinib are in the five to six months range. Silevertinib is doubling the median PFS of currently available treatments.

Sergey YurasovChief Medical Officer

Now, turning to the benefit we are seeing in the 24 patients in our study without baseline brain metastasis, the results are remarkable. With nearly 16 months of median follow-up, none of these 24 patients have progressed in the brain. I should remind you that every patient in our study gets a brain MRI every six weeks. So, even if a patient developed an asymptomatic brain metastasis, it would be detected by an MRI. These surveillance scans are often missing in other trials. Our patients without baseline brain metastasis demonstrate a median PFS of 23.5 months, almost two years. For context, osimertinib is at 9.8 months in these patients. Finally, our overall incidence of CNS progression is one-quarter of what is seen in patients who receive afatinib.

Sergey YurasovChief Medical Officer

This impressive data allowed us to align with the FDA on a differentiated path to approval that no one else can take on right now, because they lack the robust CNS data that we have. Our end-of-phase II meeting with the FDA was the most collaborative meeting I've had in my 20 years in the industry, and we got everything we hoped for out of the meeting. The first critical win is the definition of our patient population, because it is simply all oncogenic EGFR mutations, excluding the two classical mutations, exon 19 del and L858R, and exon 20 insertions. There was no PACC discussion. There was no alphabet soup of mutations. The FDA recognized our robust data showing activity across a broad group of non-classical mutations, far more than any of our competitors. So, our patient population is the entire group of non-classical EGFR mutations.

Sergey YurasovChief Medical Officer

Next, the feedback we got from the FDA on our study endpoint is, I think, what makes this trial such an exciting opportunity for us. The FDA recognized the fact that for a drug to be successful in frontline non-small cell lung cancer, showing brain activity is key. If you win in the brain, you win overall. That is why our endpoint for accelerated approval is CNS ORR per RANO-BM criteria, not systemic ORR per RECIST. Systemic ORR, and this is direct FDA language, just needs to be similar to the control, with OS showing no detriment versus the control. That is a huge fundamental difference from what anyone else must show. Then, of course, full approval is based on systemic PFS per RECIST, as is common practice in frontline lung cancer trials. Finally, on dose. This was a simple and short conversation.

Sergey YurasovChief Medical Officer

The FDA reviewed all the data we provided from dosing over 200 patients with this drug, and they acknowledged our rationale for the 150 milligram dose. All they asked us to do is provide safety data from a sufficient number of patients dosed at 150 milligram dose before enrollment starts in our phase III. We expect to deliver those data in the second quarter of 2027, as we have been enrolling patients at 150 milligram in cohort four of our ongoing phase II trial since August. This FDA meeting was a home run for us, and together with our data, allowed us to design a differentiated phase III trial that positions silevertinib, if approved, to be the drug of choice for all frontline patients with EGFR non-classical mutations. Our planned phase III trial will enroll patients with non-classical mutations, which are routinely detected by standard NGS testing.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day